Crescent Biopharma Q2 Loss Narrows to $24.8M; Pro Forma Cash Hits $305M, Runway Into 2028
CBIO sits 69% above its 52-week low of $8.72.
Summary
Crescent Biopharma posted a $24.8M Q2 net loss, initiated key clinical trials, and ended June with $171.6M in cash — pro forma $305.1M after a July offering, extending runway into 2028.
Key Events · Earnings and Guidance · CBIO
-
Q2 Net Loss Narrows
Net loss of $24.8M in Q2 2026 vs $21.8M in Q2 2025; six-month loss of $48.1M vs $36.9M. R&D spend rose to $19.4M (Q2) and $37.3M (H1) as clinical programs advanced.
-
Pro Forma Cash of $305.1M
Cash and equivalents of $171.6M at June 30, 2026, plus $133.5M net from July 2026 public offering, provides runway into 2028.
-
Clinical Milestones Achieved
ASCEND Phase 1/2 trial of CR-001 initiated; CR-003 Phase 1/2 started in China; CR-002 Phase 1/2 expected H2 2026. Kelun began Phase 2 combo study of sac-TMT + CR-001 in NSCLC.
-
ATM Program Established
On July 1, 2026, the company entered a $200M at-the-market equity program with Jefferies; no shares sold to date.
Analysis · CBIO · Life Sciences
Crescent Biopharma reported a smaller-than-expected Q2 net loss of $24.8 million, down from $48.1 million in the first half, with pro forma cash of $305.1 million after the July offering — enough to fund operations into 2028. The quarter saw the initiation of the pivotal ASCEND trial for lead asset CR-001 and the first patient dosed in a Phase 1/2 trial of CR-003 in China. A new $200 million at-the-market program adds financial flexibility but also creates an overhang. The results reinforce the company's ability to execute its clinical strategy while maintaining a strong balance sheet, though the path to revenue remains years away.
At the time of this filing, CBIO was trading at $14.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $545.9M. The 52-week trading range was $8.72 to $27.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.